Our Health Library information does not replace the advice of a doctor. Please be advised that this information is made available to assist our patients to learn more about their health. Our providers may not see and/or treat all topics found herein.

imdevimab

Pronunciation: im DEV i mab

What is the most important information I should know about imdevimab?

The FDA has authorized emergency use of imdevimab in combination with casirivimab only in people with COVID-19 who are not in a hospital or using supplemental oxygen.

Imdevimab has not been approved to treat coronavirus or COVID-19. It is not yet known if this medicine is an effective treatment for any condition.

What is imdevimab?

Imdevimab is an experimental medicine being studied for use in treating conditions caused by coronavirus. It is not yet known if imdevimab is a safe and effective treatment for any condition.

The US Food and Drug Administration (FDA) has authorized emergency use of imdevimab in combination with another medicine called casirivimab in people who test positive for COVID-19, to treat COVID-19 symptoms that could become severe enough to need treatment in a hospital or cause death.

Imdevimab and casirivimab are also for use in people who have been exposed to COVID-19 and:

  • are not fully vaccinated against COVID-19; or
  • are vaccinated but may not have built up enough immunity (because they have certain diseases or use certain medicines), and have been or may be exposed to people who are infected with COVID-19.

Imdevimab and casirivimab are for use in adults and children at least 12 years old who weigh at least 88 pounds (40 kilograms).

The risk of COVID-19 symptoms becoming severe may be higher in people who:

  • are overweight;
  • have chronic kidney disease;
  • have diabetes;
  • have a weak immune system (caused by disease or by using certain medicine);
  • have sickle cell disease;
  • have a heart problem or high blood pressure;
  • have a neurodevelopmental disorder such as cerebral palsy;
  • have asthma or other chronic breathing disorder; or
  • have a tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19).

There also may be a higher risk of severe COVID-19 symptoms in pregnant women and in adults who are 65 and older.

Imdevimab and casirivimab are mixed together into a single solution called Regen-Cov.

Imdevimab and casirivimab have not been approved to treat coronavirus or COVID-19. However, these medicines may help prevent the need for emergency medical care or admission to a hospital because of COVID-19. Regen-Cov is not authorized for use in people who are already in the hospital or receiving supplemental oxygen for COVID-19.

Imdevimab may also be used for purposes not listed in this medication guide.

What should I discuss with my healthcare provider before receiving imdevimab?

Tell your doctor if you have ever had:

  • a COVID-19 vaccine;
  • a severe allergic reaction to a COVID-19 vaccine;
  • any serious or chronic illness;
  • any allergies; or
  • if you are pregnant or breastfeeding.

COVID-19 is more likely to cause serious illness or death in a pregnant woman. Not all risks are known yet, but being treated with imdevimab and casirivimab is likely to be less harmful than being infected with COVID-19 during pregnancy.

How is imdevimab given?

Imdevimab and casirivimab (Regen-Cov) must be given as a combination. Imdevimab should not be used alone.

Regen-Cov is injected under the skin or into a vein by a healthcare provider.

When injected into a vein, Regen-Cov is given slowly over 20 to 50 minutes or longer. When injected under the skin, Regen-Cov is given as 2 to 4 separate injections into different areas of your body.

You will be watched for a short time after injection, to make sure you do not have an allergic reaction.

Regen-Cov is usually given as only one dose as soon as possible after you are exposed to or test positive for COVID-19, or within 10 days after the start of symptoms. You may need additional monthly doses if you continue to be exposed to COVID-19.

Being treated with Regen-Cov will not make you less contagious to other people. Keep using infection control methods such as self-isolation, social distancing, hand-washing, using protective face covering, disinfecting surfaces you touch a lot, and not sharing personal items with others.

Regen-Cov also may not keep you from becoming infected with coronavirus again. Being treated with this drug combination could also affect your body's immune response to a coronavirus vaccine. Imdevimab and casirivimab are still being studied and all of their risks are not yet known.

What happens if I miss a dose?

Call your doctor for instructions if you are on a monthly dose schedule and you miss an appointment for your injection.

What happens if I overdose?

In a medical setting an overdose would be treated quickly.

What should I avoid after receiving imdevimab?

Follow your doctor's instructions about any restrictions on food, beverages, or activity.

What are the possible side effects of imdevimab?

Get emergency medical help if you have signs of an allergic reaction: hives, itching; difficult breathing; swelling of your face, lips, tongue, or throat.

Some side effects may occur during the injection. Tell your caregiver right away if you have:

  • throat irritation, swelling in your face or throat;
  • dizziness, a light-headed feeling (like you might pass out);
  • chest pain, wheezing, shortness of breath;
  • fever, chills, sweating, nausea, flushing (sudden warmth, redness, or tingly feeling);
  • fast or slow heartbeats, headache, pounding in your neck or ears;
  • weakness, tiredness;
  • rash, itching; or
  • muscle pain.

Call your doctor if you have new or worsening symptoms after the infusion, such as fever, confusion, weakness, tiredness, trouble breathing, or fast or slow heartbeats.

Less serious side effects may also occur, or you may have none at all. Not all possible side effects are known.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect imdevimab?

Other drugs may affect imdevimab, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.

Where can I get more information?

Your doctor or pharmacist can provide more information about imdevimab.

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 1996-2021 Cerner Multum, Inc. Version: 4.01. Revision date: 8/9/2021.

Your use of the content provided in this service indicates that you have read, understood and agree to the End-User License Agreement, which can be accessed by End-User License Agreement, which can be accessed by clicking on this link.